FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock (Q73453315)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

Yamamoto N

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sakai F

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Yamazaki H

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Sato N

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Nakahara K

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Okuhara M

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 May 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Pharmacology

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

169-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon- , and Interferon- in the Serum of Patients with Septic Shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Multiple-organ-failure syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Nitric oxide and septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

The role of interleukin-1 in disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2989657-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(97)89657-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9200556%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference